Your browser doesn't support javascript.
loading
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Thorax ; 67(1): 12-8, 2012 Jan.
Article in En | MEDLINE | ID: mdl-21825083

Full text: 1 Database: MEDLINE Main subject: DNA / Cystic Fibrosis Transmembrane Conductance Regulator / Cystic Fibrosis / Benzodioxoles / Aminopyridines / Mutation Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Thorax Year: 2012 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: DNA / Cystic Fibrosis Transmembrane Conductance Regulator / Cystic Fibrosis / Benzodioxoles / Aminopyridines / Mutation Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Thorax Year: 2012 Type: Article Affiliation country: United States